Korro Bio (NASDAQ:KRRO) Stock, Quote.Headers.trade-ideas

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Stock market analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALAB

ENGN

INGM

KRRO

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Newark,,Nj,-15,Sep,2017-,Planes,From,United,Airlines,(ua)

Intraday Update

Movers

AMPS

ASPN

OKLO

United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

Biotech

Earnings

Large Cap

Health Care

Price Target

Offerings

Small Cap

Federal Reserve

Tech

General

ASML

AVGO

IFNNF

U.S. stocks reacted positively following the Federal Open Market Committee&#39;s announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated.

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Korro Bio Inc

<p>Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Dollar Gen, presenting an average target of $89.07, a high estimate of $104.00, and a low estimate of $80.00. This current average represents a 8.65% decrease from the previous average price target of $97.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482456_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Dollar Gen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$96.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$83.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$95.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$90.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$97.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dollar Gen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dollar Gen compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Dollar Gen's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Dollar Gen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dollar Gen analyst ratings.</strong></a></p>
<h2>About Dollar Gen</h2>
<p>With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged and perishable food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.</p>
<h3>Financial Insights: Dollar Gen</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Dollar Gen's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>5.05%</strong> as of 31 October, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Dollar Gen's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>1.93%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dollar Gen's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.69%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Dollar Gen's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.62%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.39</strong>, Dollar Gen faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Dollar Gen Through The Eyes Of 14 Analysts

<p>Throughout the last three months, 7 analysts have evaluated Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Bread Finl Hldgs, revealing an average target of $61.0, a high estimate of $88.00, and a low estimate of $34.00. Witnessing a positive shift, the current average has risen by 10.33% from the previous average price target of $55.29.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482449_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Bread Finl Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$58.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Bill Ryan</td>
<td>Seaport Global</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Moshe Orenbuch</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bread Finl Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bread Finl Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Bread Finl Hldgs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Bread Finl Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BFH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bread Finl Hldgs analyst ratings.</strong></a></p>
<h2>Get to Know Bread Finl Hldgs Better</h2>
<p>Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains minority interest in its recently spun-off LoyaltyOne division, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.</p>
<h3>Financial Insights: Bread Finl Hldgs</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Bread Finl Hldgs's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-4.66%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Bread Finl Hldgs's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>0.2%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bread Finl Hldgs's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.06%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Bread Finl Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.01%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Bread Finl Hldgs's debt-to-equity ratio is below the industry average at <strong>1.47</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Bread Finl Hldgs Stock: Analyst Perspectives (7 Ratings)

<p>Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.25, a high estimate of $82.00, and a low estimate of $77.00. This current average reflects an increase of 6.38% from the previous average price target of $74.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482440_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Independent Bank. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher O'Connell</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Steve Moss</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$78.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Christopher O'Connell</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$82.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Christopher O'Connell</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$77.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Independent Bank. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Independent Bank compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Independent Bank's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Independent Bank's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INDB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Independent Bank analyst ratings.</strong></a></p>
<h2>Discovering Independent Bank: A Closer Look</h2>
<p>Independent Bank Corp is a bank holding company and the sole shareholder of its bank, the Rockland Trust Company. Rockland is a community-oriented commercial bank. The bank provides a variety of banking, investment and financial services, operating with various retail branches, as well as a network of commercial and residential lending centers, and investment management offices majorly in Eastern Massachusetts, Worcester County, and Rhode Island. The bank's loan portfolio constitutes the bulk of the bank's total assets. Its borrowers consist mostly of small to medium-size businesses and consumers, majority of which are made to its market area in eastern Massachusetts and Rhode Island. The bank's loan portfolio is predominantly in commercial loans.</p>
<h3>Independent Bank's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Independent Bank's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-3.57%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Independent Bank's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>24.59%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Independent Bank's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.46%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Independent Bank's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.22%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Independent Bank's debt-to-equity ratio is below the industry average at <strong>0.22</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


INDB

Demystifying Independent Bank: Insights From 4 Analyst Reviews

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>RTX</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RTX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for RTX.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $71,784, and 8 are calls, for a total amount of $334,729.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $112.0 to $130.0 for RTX during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of RTX stands at 1883.33, with a total volume reaching 1,669.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in RTX, situated within the strike price corridor from $112.0 to $130.0, throughout the last 30 days.</p>
<h3>RTX 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482438_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.05</td>
<td>$4.95</td>
<td>$5.08</td>
<td>$125.00</td>
<td>$67.2K</td>
<td>4.3K</td>
<td align="right">157</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$7.25</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$120.00</td>
<td>$56.8K</td>
<td>1.4K</td>
<td align="right">94</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.35</td>
<td>$7.3</td>
<td>$7.35</td>
<td>$120.00</td>
<td>$52.1K</td>
<td>1.4K</td>
<td align="right">103</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$3.1</td>
<td>$2.9</td>
<td>$3.0</td>
<td>$125.00</td>
<td>$43.5K</td>
<td>4.1K</td>
<td align="right">24</td>
</tr>
<tr>
<td>RTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.92</td>
<td>$1.74</td>
<td>$1.74</td>
<td>$120.00</td>
<td>$37.5K</td>
<td>2.8K</td>
<td align="right">220</td>
</tr>
</tbody>
</table>
</p>
<h3>About RTX</h3>
<p>RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace and to the defense market. The company operates in three segments: Collins Aerospace, a diversified aerospace supplier; Pratt &amp; Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.</p>
<p>In light of the recent options history for RTX, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is RTX Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,081,373, with RTX's price up by 3.53%, positioned at $125.38.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>What The Experts Say On RTX</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $145.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on RTX, which currently sits at a price target of $139.<br />
&#x2A; An analyst from Citigroup upgraded its action to Buy with a price target of $153.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on RTX with a target price of $151.<br />
&#x2A; An analyst from Deutsche Bank upgraded its action to Buy with a price target of $140. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest RTX options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Spotlight on RTX: Analyzing the Surge in Options Activity

<p>America&#8217;s artificial intelligence boom is triggering an <a href="https://www.benzinga.com/24/12/42349552/is-the-mag-7s-ai-boom-supercharging-a-natural-gas-revolution">unexpected surge in natural gas power plant construction</a>, upending clean energy forecasts and culminating in Constellation Energy&#8217;s $27 billion acquisition of gas giant Calpine.</p>
<p>Energy consultancy Enverus projects that 80 new gas-fired plants will be built across the United States by 2030, adding 46 gigawatts of power capacity – equivalent to Norway&#8217;s entire electrical system, according to a report issued by the Financial Times. The expansion marks a 20% increase over the past five years&#8217; construction pace and reverses earlier predictions of declining gas capacity.</p>
<p>&#8220;Gas is actually growing faster now and in the medium term, than ever before,&#8221; Enverus research analyst Corianna Mah told the Financial Times.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
</ul>
<p>Major tech companies <a href="https://www.benzinga.com/government/regulations/25/01/42865106/trump-vows-to-power-ai-boom-with-expanded-oil-drilling-need-double-the-electricity-at-least-that-we-have-right-now">are driving the fossil fuel renaissance</a>. Meta recently announced plans to power its $10 billion AI data center through Entergy&#8217;s $3.2 billion gas plant expansion. Once the facility comes online, the social media giant will become the utility&#8217;s largest customer.</p>
<p>The Department of Energy expects AI-related electricity demand from data centers to triple within three years. The surge caught even industry veterans off guard. &#8220;I wish I could&#8217;ve predicted it 18 months ago,&#8221; said Bill Newsom, CEO of turbine manufacturer Mitsubishi Power Americas, which now plans to boost production capacity by 50%.</p>
<p>Traditional energy companies are rushing to capitalize. ExxonMobil and Chevron are designing plants to supply AI data centers directly while utilities keep aging facilities running longer than planned. Wood Mackenzie has cut its 2035 forecast for gas plant retirements by 10%.</p>
<p><strong>See Also: With 100+ historic trademark victories, this company holds IP for some of the highest-grossing characters in history. Now, they've propelled these icons into the future using next-gen patented AR, VR, and AI technology. <a href="https://www.benzinga.com/money/elf-labs-1"><strong>There&#8217;s now a limited window for investors to claim shares at just $2/share with $980 minimum—but the clock is ticking.</strong></a></strong></p>
<p>The construction wave threatens the Biden administration&#8217;s climate goals, which target a 50% emissions cut by the decade&#8217;s end. According to data from energy think tank Ember cited by the Financial Times, U.S. gas plants released over one billion tons of carbon dioxide last year – their highest output on record.</p>
<p>While renewable energy development continues, industry leaders say current battery technology can&#8217;t match gas plants&#8217; reliability for power-hungry AI operations. &#8220;Your ability to serve that kind of load reliably is very limited with traditional renewables,&#8221; Matt Bulpitt, Entergy&#8217;s vice president of power development, said to Financial Times.</p>
<p>Texas, Tennessee and South Carolina led the gas expansion. None of the planned facilities will include carbon capture systems, equipment that would become mandatory in 2032 under Biden-era rules likely to face rollback under Trump&#8217;s second term.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce"><strong>this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</strong></a></strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>


'I Wish I Could've Predicted It': The $27 Billion Gas Deal Behind AI's Energy Appetite

<p>In the last three months, 6 analysts have published ratings on LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $68.17, a high estimate of $78.00, and a low estimate of $58.00. Surpassing the previous average price target of $62.60, the current average has increased by 8.9%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482432_0_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of LendingTree by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to LendingTree. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of LendingTree compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for LendingTree's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of LendingTree's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TREE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on LendingTree analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind LendingTree</h2>
<p>LendingTree Inc is a United States-based company that is principally engaged in operating an online loan marketplace. The company provides online tools and resources that can help consumers find loans or other credit-based offerings They need, including mortgage loans, reverse mortgage, home equity, personal loans, auto loans, credit cards, student loans, small business loans, and other related offerings. The company offers consumers direct access to a broad range of lenders. They have three reportable segments which are Home, Consumer, and Insurance. The company generates match fees by matching consumers with lenders, and closing fees from lenders on loans when a transaction is closed. The company operates business solely in the United States.</p>
<h3>LendingTree: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> LendingTree's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>68.05%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> LendingTree's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-22.23%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> LendingTree's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-48.3%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> LendingTree's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-7.3%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>5.82</strong>, LendingTree faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TREE

6 Analysts Have This To Say About LendingTree

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>NextEra Energy</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NEE, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for NextEra Energy.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $333,725, and 8 are calls, for a total amount of $553,754.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $57.5 to $100.0 for NextEra Energy during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for NextEra Energy options trades today is 489.71 with a total volume of 7,384.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for NextEra Energy's big money trades within a strike price range of $57.5 to $100.0 over the last 30 days.</p>
<h3>NextEra Energy Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482432_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.35</td>
<td>$2.21</td>
<td>$2.31</td>
<td>$57.50</td>
<td>$231.0K</td>
<td>495</td>
<td>1.0K</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$0.79</td>
<td>$0.72</td>
<td>$0.75</td>
<td>$77.50</td>
<td>$158.0K</td>
<td>2.6K</td>
<td>3.6K</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.21</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$72.00</td>
<td>$126.8K</td>
<td>0</td>
<td>575</td>
</tr>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$29.35</td>
<td>$28.85</td>
<td>$29.35</td>
<td>$100.00</td>
<td>$102.7K</td>
<td>45</td>
<td>35</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$0.75</td>
<td>$0.72</td>
<td>$0.75</td>
<td>$77.50</td>
<td>$75.0K</td>
<td>2.6K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About NextEra Energy</h3>
<p>NextEra Energy's regulated utility, Florida Power &amp; Light, is the largest rate-regulated utility in Florida. The utility distributes power to nearly 6 million customer accounts in Florida and owns 34 gigawatts of generation. FP&amp;L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 34 GW of generation capacity, including natural gas, nuclear, wind, and solar.</p>
<p>In light of the recent options history for NextEra Energy, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is NextEra Energy Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,662,056, the price of NEE is up by 0.6%, reaching $71.19.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 3 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for NextEra Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


NextEra Energy's Options: A Look at What the Big Money is Thinking

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Reviva Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RVPH, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Reviva Pharmaceuticals.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 9% bullish and 90%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $663,591, and 3 are calls, for a total amount of $83,209.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $2.0 to $5.0 for Reviva Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Reviva Pharmaceuticals's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Reviva Pharmaceuticals's whale activity within a strike price range from $2.0 to $5.0 in the last 30 days. </p>
<h3>Reviva Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482427_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RVPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.5</td>
<td>$5.00</td>
<td>$194.9K</td>
<td align="right">689</td>
<td>1.7K</td>
</tr>
<tr>
<td>RVPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.6</td>
<td>$3.1</td>
<td>$3.6</td>
<td>$5.00</td>
<td>$122.4K</td>
<td align="right">689</td>
<td>774</td>
</tr>
<tr>
<td>RVPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.6</td>
<td>$2.9</td>
<td>$3.6</td>
<td>$5.00</td>
<td>$115.2K</td>
<td align="right">689</td>
<td>374</td>
</tr>
<tr>
<td>RVPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.5</td>
<td>$3.1</td>
<td>$3.5</td>
<td>$5.00</td>
<td>$76.6K</td>
<td align="right">689</td>
<td>2.0K</td>
</tr>
<tr>
<td>RVPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.5</td>
<td>$2.7</td>
<td>$3.5</td>
<td>$5.00</td>
<td>$44.8K</td>
<td align="right">689</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Reviva Pharmaceuticals</h3>
<p>Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.</p>
<h3>Where Is Reviva Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a volume of 2,226,838, the price of RVPH is up 4.52% at $1.85. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>What The Experts Say On Reviva Pharmaceuticals</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $9.666666666666666.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from D. Boral Capital persists with their Buy rating on Reviva Pharmaceuticals, maintaining a target price of $15.<br />
&#x2A; Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $7.<br />
&#x2A; An analyst from Maxim Group has elevated its stance to Buy, setting a new price target at $7. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Reviva Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RVPH

Reviva Pharmaceuticals Unusual Options Activity

<p>Across the recent three months, 12 analysts have shared their insights on GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $211.92, a high estimate of $251.00, and a low estimate of $176.00. Witnessing a positive shift, the current average has risen by 13.43% from the previous average price target of $186.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482423_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive GoDaddy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$230.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Elizabeth Elliott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$227.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$251.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$224.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$172.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GoDaddy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GoDaddy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for GoDaddy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of GoDaddy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GDDY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on GoDaddy analyst ratings.</strong></a></p>
<h2>Delving into GoDaddy's Background</h2>
<p>GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.</p>
<h3>GoDaddy: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, GoDaddy showcased positive performance, achieving a revenue growth rate of <strong>7.28%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> GoDaddy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>16.6%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>74.17%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> GoDaddy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.42%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>10.97</strong>, GoDaddy faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GDDY

Deep Dive Into GoDaddy Stock: Analyst Perspectives (12 Ratings)

<p>Barclays  analyst Terence Malone   downgrades BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) from Equal-Weight to Underweight.</p>


Downgrades

Barclays Downgrades BCE to Underweight

<p>Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.0, a high estimate of $25.00, and a low estimate of $17.00. Highlighting a 9.68% decrease, the current average has fallen from the previous average price target of $23.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737482414_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Jamf Holding's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jamf Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jamf Holding compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Jamf Holding's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Jamf Holding's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JAMF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Jamf Holding analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Jamf Holding: A Closer Look</h2>
<p>Jamf Holding Corp is the standard in Apple Enterprise Management, and its cloud software platform is the vertically focused Apple infrastructure and security platform. The company helps organizations, including businesses, hospitals, schools, and government agencies, connect, manage, and protect Apple products, apps, and corporate resources in the cloud without ever having to touch the devices. It sells its Software-as-a-Service, or SaaS, solutions via a subscription model, through a direct sales force, online, and indirectly via its channel partners, including Apple. The company operates in The Americas; Europe, the Middle East, India, and Africa; and Asia Pacific.</p>
<h3>Jamf Holding: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Jamf Holding displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>11.68%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Jamf Holding's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-7.68%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Jamf Holding's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-1.73%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Jamf Holding's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-0.78%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Jamf Holding's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.51</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


JAMF

Deep Dive Into Jamf Holding Stock: Analyst Perspectives (4 Ratings)

<p>Morgan Stanley  analyst Keith Weiss   maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Overweight and raises the price target from $130 to $140.</p>


Morgan Stanley Maintains Overweight on Cloudflare, Raises Price Target to $140

<p>Barclays  analyst Kannan Venkateshwar   downgrades Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) from Overweight to Equal-Weight.</p>


Barclays Downgrades Rogers Communications to Equal-Weight

<p><strong>Amazon.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)&nbsp;paused <a href="https://www.benzinga.com/topic/drones" target="_blank" rel="noreferrer noopener">commercial drone</a> delivery last Friday in Texas and Arizona to fix the aircraft&#8217;s software.</p>
<p>The suspension followed the crash of two of its latest models at a testing facility in rainy weather, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-01-17/amazon-pauses-drone-deliveries-after-aircraft-crashed-in-rain?sref=TBDibEcD" rel="noreferrer noopener">reports</a>.</p>
<p>Amazon and <strong>Walmart Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) have <a target="_blank" href="https://www.benzinga.com/top-stories/24/06/39192891/amazon-vs-walmart-who-will-be-the-first-to-conquer-the-skies-with-drone-delivery" rel="noreferrer noopener">splurged billions to</a> develop drone delivery technology. Amazon created the technology in-house while Walmart collaborated with Zipline and <strong>Alphabet Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s Wing.</p>
<p><strong>Also Read: </strong><a href="https://www.benzinga.com/tech/25/01/43008511/broadcoms-latest-san-switch-offers-scalable-energy-efficient-solution-for-growing-storage-demands" target="_blank" rel="noreferrer noopener">Broadcom&#8217;s Latest SAN Switch Offers Scalable, Energy-Efficient Solution for Growing Storage Demands</a></p>
<p>Drone delivery services will likely become a&nbsp;$10 billion industry&nbsp;by the decade&#8217;s end.</p>
<p>Amazon&#8217;s drone operation <a target="_blank" href="https://www.benzinga.com/markets/equities/24/05/39093895/amazons-drone-program-to-expand-with-new-faa-clearance-whats-on-the-move" rel="noreferrer noopener">aims to deliver</a> 500 million packages annually by the decade&#8217;s end.</p>
<p>Eleven years ago, Amazon founder&nbsp;Jeff Bezos&nbsp;shared plans to build drones capable of delivering products to customers in less than half an hour.</p>
<p>In December, two MK30 drones crashed during flights at the airport in Pendleton, Oregon, which Amazon uses for testing.</p>
<p>The company later discovered a software issue that caused the accident.</p>
<p>The MK30 drones, cleared to commence operations by the Federal Aviation Administration in October, have delivered packages to customers&#8217; homes in College Station, Texas, and Tolleson, Arizona.</p>
<p>Amazon representative Sam Stephenson told Bloomberg that deliveries will resume after the FAA approval.</p>
<p>Stephenson emailed Bloomberg, stating Amazon&#8217;s drones continued to deliver safely and within federal guidelines between the December crashes and Friday&#8217;s halt.</p>
<p>In December, the company completed its <a href="https://www.benzinga.com/news/23/10/35323630/amazons-drone-delivery-service-to-extend-to-uk-and-italy" target="_blank" rel="noreferrer noopener">first test flight</a> in Italy and plans to expand its service this year. It is also targeting the start of deliveries in the U.K.</p>
<p>Goldman Sachs&#8217;<strong> Eric Sheridan</strong> <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42899163/goldman-sachs-analyst-is-bullish-on-amazon-but-not-ebay-or-etsy" target="_blank" rel="noreferrer noopener">expressed optimism about</a> Amazon&#8217;s customer loyalty, backed by its subscription. The analyst flagged Amazon&#8217;s exposure to less discretionary categories (experiencing volatility in online spending from lower incomes) with high repeat behavior through subscriptions and essentials purchasing.</p>
<p>Amazon stock surged over 48% in the past 12 months. Investors can gain exposure to the stock through <strong>ProShares Online Retail ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>) and <strong>Vanguard Consumer Discretion ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCR#NYSE">VCR</a>).</p>
<p><strong>AMZN</strong> <strong>Price Action:</strong> Amazon stock is up 2.42% at $231.42 last check Tuesday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/media/25/01/43004444/intel-plans-to-spin-off-5-billion-venture-capital-segment-will-remain-anchor-investor" target="_blank" rel="noreferrer noopener">Intel Plans To Spin Off $5 Billion Venture Capital Segment, Will Remain Anchor Investor</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Media

AMZN

GOOG

GOOGL

ONLN

Amazon Pauses Drone Deliveries In Texas, Arizona After Crashes, Plans Safety Upgrades

<p>Oppenheimer  analyst Martin Yang   maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and lowers the price target from $170 to $165.</p>


Oppenheimer Maintains Outperform on Electronic Arts, Lowers Price Target to $165

<p>On Friday, the U.S. Food and Drug Administration (FDA) approved <strong>AstraZeneca Plc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Datroway&nbsp;(datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy <a target="_blank" href="https://www.benzinga.com//node/43069016" rel="noreferrer noopener">for unresectable or metastatic disease.</a></p>
<p>The approval was based on results from the&nbsp;TROPION-Breast01&nbsp;Phase 3 trial.</p>
<p><strong>Read Next: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43065029/astrazeneca-aims-to-restore-trust-with-new-leadership-in-china-amid-scandal-and-sales-decline" rel="noreferrer noopener">AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline</a></strong></p>
<p>In TROPION-Breast01,&nbsp;Datroway&nbsp;significantly reduced the risk of disease progression or death by 37% compared to the investigator&#8217;s choice of chemotherapy as assessed by blinded independent central review (BICR). Median progression-free survival (PFS) was 6.9 months in patients treated with&nbsp;Datroway&nbsp;versus 4.9 months with chemotherapy.</p>
<p>The safety profile of&nbsp;Datroway&nbsp;was consistent with the known profile of this medicine, with no new safety concerns identified.</p>
<p>In the&nbsp;Datroway&nbsp;arm, the interstitial lung disease (ILD) rate was 4.2% and the majority of events were low grade.</p>
<p>Datroway&nbsp;is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by<strong> Daiichi Sankyo</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>), and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.</p>
<p>Recently, the FDA approved&nbsp;AstraZeneca&#8217;s Calquence in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43062308/fda-approves-astrazenecas-calquence-combo-therapy-for-untreated-mantle-cell-lymphoma" rel="noreferrer noopener">stem cell transplantation.</a></p>
<p><strong>Price Action:</strong> AZN stock is up 2.43% at $68.22 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43100176/charles-schwab-delivers-strong-q4-higher-trading-volumes-and-increased-assets-drive-growth" target="_blank" rel="noreferrer noopener">Charles Schwab Delivers Strong Q4: Higher Trading Volumes And New Assets Drive Growth</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Equities

DSKYF

DSNKY

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

<p>Needham  analyst Serge Belanger   reiterates Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy and maintains $22 price target.</p>


Reiteration

EOLS

Needham Reiterates Buy on Evolus, Maintains $22 Price Target

<p>Oppenheimer  analyst Martin Yang   maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and raises the price target from $190 to $215.</p>


TTWO

Oppenheimer Maintains Outperform on Take-Two Interactive, Raises Price Target to $215

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

$BTC

$ETH

U.S. SEC Says Acting Chairman Uyeda Announces Formation Of New Crypto Task Force; New Crypto Task Force Will Be Dedicated To Developing A Comprehensive And Clear Regulatory Framework For Crypto Assets; Senior Advisors Gabbert And Asher Will Serve As Task Force's Chief Of Staff And Chief Policy Advisor, Respectively

<p>Traders and investors are watching for <strong>Discover Financial Services</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) <a href="https://www.benzinga.com/quote/DFS/earnings">fourth-quarter financial results</a>, confirmed for Wednesday&#8217;s after hours session.</p>
<p>With earnings per share of $3.69 and revenue surpassing expectations at $4.453 billion, Discover in the third quarter benefitted from increased net interest margins and <a href="https://www.benzinga.com/news/earnings/24/10/41369150/discover-reports-better-than-expected-q3-results-higher-delinquency-rates-yoy-details">steady loan growth</a>. </p>
<p><strong>What To Know From Q3:</strong> Credit card loans rose by 3%, and personal loans grew by 9%, contributing to an overall 4% year-over-year loan increase. The company's strategic move to reduce its private student loan portfolio is expected to continue impacting results, but the improved credit profile and net interest income should provide a boost.</p>
<p>While the delinquency rates showed slight increases in both 30+ day and 90+ day categories, Discover&#8217;s risk management initiatives remain a priority. The company&#8217;s Payment Services division, although stable, could see growth from debit transaction volume as PULSE volume increased by 14%. </p>
<p>As Discover wraps up its student loan portfolio sale, the company could be well-positioned for growth, bolstered by its robust digital banking business and expanding margins.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/tech/25/01/43092840/tesla-struggles-in-europe-as-new-registrations-fall-13-in-2024-driving-first-global-delivery-decline-in-years">Tesla Struggles in Europe As New Registrations Fall 13% In 2024, Driving First Global Delivery Decline In Years</a></strong></p>
<h2 class="wp-block-heading">How To Buy DFS Stock</h2>
<p>By now you're likely curious about how to participate in the market for Discover Financial &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.</p>

<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DFS has a 52-week high of $189.65 and a 52-week low of $97.70.</p>


What's Going On With Discover Financial Services (DFS) Stock?

Catherine Novack, an analyst from JonesTrading, has initiated a new Buy rating on Korro Bio (KRRO). Catherine Novack has given her Buy rating due t...

Korro Bio: Buy Rating Backed by Innovative RNA Editing Focus and Strategic Partnerships

Korro Bio (KRRO) announced that it has received approval from the Australian Bellberry Human Research Ethics Committee, HREC, and clearance from th...

Korro Bio receives HREC approval, CTN clearance to initiate Phase 1/2a study

Korro gets Australian HREC approval to initiate phase 1/2a study for antitrypsin deficiency

BMO Capital analyst Kostas Biliouris has maintained their bullish stance on KRRO stock, giving a Buy rating today. Kostas Biliouris has given his B...

Korro Bio: Advancing RNA Editing with Promising Clinical and Market Potential

16:23 EST Korro Bio (KRRO) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Korro Bio files $400M mixed securities shelf

Biopharma Korro Bio ($KRRO) has been making significant strides in genetic medicine, including developing RNA editing to address rare and widesprea...

Why Korro Bio (KRRO) Should Be on Your Investment Radar

Korro Bio: Still Too Long To Go... Just Keep Watching For Now (Rating Upgrade)

Oppenheimer analyst Andreas Argyrides initiated coverage of Korro Bio (KRRO) with an Outperform rating and $155 price target Published first on The...

Korro Bio initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Korro Bio (KRRO) with an Outperform rating and $155 price target The company's Opera platform enables precise RNA...

Korro initiated with Outperform into 2025 catalysts at Oppenheimer

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Korro Bio (KRRO – Research Report) yesterday and set a price target of $120.00. Kos...

Korro Bio's RNA Editing Potential: A Buy Rating with Promising Catalysts and Commercial Opportunities

Press Releases

Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro to Present at the Jefferies London Healthcare Conference

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Participate in Upcoming Investor Conferences

Management

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

Comments

Korro Bio

Korro Bio (KRRO) Forecast

Korro Bio (NASDAQ:KRRO) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga